Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AOC3 | Q16853 | 13/20 | 0.49 |
| ▸ | CYP17A1 | P05093 | 1/20 | 0.42 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.41 |
| ▸ | NAMPT | P43490 | 1/20 | 0.41 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.41 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.41 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.41 |
| ▸ | GLS | O94925 | 1/20 | 0.41 |
| ▸ | LCK | P06239 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4883904 | 0.91 | AOC3 (0.48) | AOC3CYP17A1HDAC1HDAC6RXFP1 | |
| SCHEMBL4867025 | 0.90 | AOC3 (0.58) | AOC3CYP17A1HDAC1HDAC6GLS | |
| SCHEMBL28759633 | 0.88 | AOC3 (0.46) | AOC3CYP17A1HDAC1HDAC6GLS | |
| SCHEMBL4866969 | 0.87 | AOC3 (0.55) | AOC3CYP17A1RXFP1GLS | |
| SCHEMBL4874746 | 0.87 | CYP17A1 (0.45) | AOC3CYP17A1HDAC1HDAC6GLS | |
| SCHEMBL4985325 | 0.86 | AOC3 (0.52) | AOC3SMN1; SMN2RXFP1 | |
| SCHEMBL27646813 | 0.86 | AOC3 (0.46) | AOC3CYP17A1HDAC1HDAC6RXFP1 | |
| SCHEMBL4878024 | 0.86 | AOC3 (0.66) | AOC3CYP17A1HDAC1HDAC6GLS | |
| SCHEMBL4872960 | 0.86 | AOC3 (0.55) | AOC3CYP17A1SMN1; SMN2GLS | |
| SCHEMBL14019606 | 0.84 | AOC3 (0.53) | AOC3SMN1; SMN2RXFP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-1794988-B | Composition for treating vascular hyperpermeable disease | SUCAMPO AG | 2010-07-28 | — | — | CN | disclosed |
| CN-100491361-C | Thiazole derivatives and their use as VAP-1 inhibitors | FUJISAWA PHARMACEUTICAL CO (JP) | 2009-05-27 | — | — | CN | disclosed |
| CN-1794988-A | Method for treating vascular hyperpermeable disease | SUCAMPO AG (CH) | 2006-06-28 | — | — | CN | disclosed |
| CN-1761655-A | Thiazole derivatives and their use as VAP-1 inhibitors | FUJISAWA PHARMACEUTICAL CO (JP) | 2006-04-19 | — | — | CN | disclosed |